Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results

Last Modified: 3/1/1994


1.		Phase Ib/IIa Study of Murine Anti-Idiotypic MOAB BEC2 with Alum Adjuvant in Patients with Advanced Melanoma (Summary Last Modified 03/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over								MSKCC-93103A1 NCI-V93-0338

Last Modified: 1/1/2000 First Published: 1/1/2000


2.		Phase I/II Study of Human Anti-Idiotypic Monoclonal Antibody Vaccine (4B5) in Patients with Stage III or IV Melanoma at High Risk for Recurrence Following Surgical Resection

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				NCI				UAB-9746 UAB-F980729009, NCI-G99-1644, NCT00004184

Last Modified: 2/7/2005 First Published: 1/1/2001


3.		Phase I/II Study of Monoclonal Antibody 105AD7 Anti-Idiotype Vaccine and ONYCR1, ONYCR2, and ONYCR3 Allogeneic Adenocarcinoma Cell-Based Vaccines in Patients With Locally Advanced or Metastatic Adenocarcinoma of the Colon or Rectum

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				ONYVAX-SGCRO01 NCI-V00-1599, NCT00007826

Last Modified: 1/1/2000


4.		Phase II Randomized Study Comparing Immunologic Responses of Stage II and III Colorectal Cancer Patients on Adjuvant Therapy Treated with 3H1 Anti-Idiotype Monoclonal Antibody Mixed with Sargramostim Versus 3H1 Anti-Idiotype Monoclonal Antibody Alum Precipitate Mixed with Sargramostim (Summary Last Modified 01/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				UKMC-95GI24CB NCI-H97-1184

Last Modified: 6/21/2006 First Published: 3/1/2002


5.		Phase II Randomized Adjuvant Study of Vaccination With Tyrosinase, gp100, and MART-1 Peptides Emulsified With Montanide ISA-51 With Interleukin-12 and Either Alum Adjuvant or Sargramostim (GM-CSF) in Patients With Resected Stage IIB, IIC, III, or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				LAC-USC-10M011 LAC-USC-IRB-013030, NCI-5506, NCT00031733, 5506

Last Modified: 1/1/2000


6.		Phase I Pilot Study of Immunotherapy with Rat Monoclonal Anti-Idiotypic Antibody BR3E4 (Ab2) with Alum as Adjuvant for Surgically Incurable Colorectal Cancer (Summary Last Modified 01/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				over 18				NCI				JMC-9309057 NCI-H96-0001

Select All on One Page